{
    "nctId": "NCT05068726",
    "briefTitle": "Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients",
    "officialTitle": "Clinical Utility of Fluoroestradiol F18 PET/CT in Metastatic Breast Cancer Patients With ER-Positive and HER2-Negative Primary Lesions After Progression on First Line Hormonal Therapy",
    "overallStatus": "TERMINATED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 51,
    "primaryOutcomeMeasure": "Evaluate change in therapeutic management plan assessed by comparing pre/post-Cerianna PET/CT treatment selection (based on comparison of the initial management plan and post-Cerianna PET/CT management plan evaluated within 3 weeks).",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patient must sign informed consent prior to enrollment in this trial\n* The patient is a female \u226518 years old\n* Post-menopausal or pre-menopausal patient with known primary breast tumor(s) expressing ER in \u22651% of tumor cells by IHC\n* HER2-negative (0, 1+, 2+ fluorescence in situ hybridization (FISH) negative) primary lesion\n* MBC with at least 1 identifiable lesion on standard-of-care imaging assessment, outside of the liver, as confirmed by the investigator site\n* Patient with progressive disease on 1st line hormonal therapy (Aromatase Inhibitor) with or without a CDK4/6 inhibitor or mechanistic target of rapamycin (mTOR) inhibitor or phosphoinositide 3-kinases (PI3K) inhibitor\n* Patient must score at least 0, 1 or 2 on the Eastern Cooperative Oncology Group (ECOG) Performance Status\n* Life expectancy of at least 12 months\n* The patient is planned to undergo a standard-of-care imaging scan (according to National Comprehensive Cancer Network guidelines, e.g., CT and/or bone scan, or fluorodeoxyglucose \\[FDG\\]-PET/CT) covering chest, abdomen, and pelvis after date of consent and before Cerianna PET/CT (Visit 2), or the patient has undergone recent standard-of-care imaging before date of consent and is planned to undergo Cerianna PET/CT (Visit 2) no more than 45 days from the standard-of-care imaging scan\n\nExclusion Criteria:\n\n* Isolated hepatic metastases (taking into account the physiological hepatic high uptake of Cerianna)\n* Patient is on tamoxifen/toremifene treatment without 8-week washout, or on fulvestrant treatment without 28-week washout, (may block ER) before Cerianna PET/CT\n* Other evolutive malignant disease (non-melanoma skin cancer is allowed) or acute or chronic infectious disease (well-controlled infectious disease is allowed);\n* Patient has a history of administered chemotherapy for metastatic disease; prior chemotherapy in the (neo)adjuvant setting is allowed\n* Patient with a known allergy to any of the components of Cerianna\n* Woman of childbearing age who is not using effective contraception\n* Pregnant woman (per the Product Label and ensured using clinic's standard-of-care), or parturient or nursing mother\n* Patient presents with any other clinically active, serious, life-threatening disease, medical, or psychiatric condition, and/or who has a life expectancy of \\<12 months, or for whom study participation may compromise their management; and/or a patient who the investigator judges to be unsuitable for participation in the study for any reason\n* Inability to comply with any requirements of the protocol",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}